ADM Tronics Reports Second Quarter of Fiscal Year 2026 Results
Rhea-AI Summary
ADM Tronics (OTCQB:ADMT) reported second fiscal quarter results for the period ended September 30, 2025. The company reported six-month revenues of $1,861,173 (an increase of over 9.6% year-over-year) and quarter revenues of $887,498 (an increase of over 5.6% versus the prior-year quarter).
Income from operations was $111,787 for the six months and $2,553 for the quarter, compared with $118,262 and a loss of $45,858 in the comparable prior periods. The company continues R&D on its Sonotron non-invasive therapeutic device and intends to submit a 510(k) premarket notification to the FDA after engineering is finalized. Full financials are available in the company Form 10-Q for September 30, 2025.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, ADMT declined 6.92%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
NORTHVALE, NJ / ACCESS Newswire / November 14, 2025 / ADM Tronics Unlimited, Inc. (OTCQB:ADMT), a technology-based developer and manufacturer of innovative technologies and products, announces results for its second fiscal quarter ended September 30, 2025 of Fiscal Year 2026.
The Company continued its positive momentum in revenues this fiscal year, building on the gains reported in the Annual 10-K Report for the fiscal year ended March 31, 2025, and the first fiscal quarter ended June 30, 2025. For this second fiscal quarter ended September 30, 2025 of the fiscal year ended March 31, 2026, ADMT achieved an increase in revenues of over
Research and development activity and expense are continuing on the Company's Sonotron ® technology, a non-invasive therapeutic medical device for the treatment of musculoskeletal pain conditions and diseases. Once engineering development is finalized, the Company intends to submit a510(k) Pre-Market Notification to the FDA seeking clearance to market the in the U.S. as a Class II prescription medical device for professional use.
Revenues for the six months ended September 30, 2025 were
Revenues for the three months ended September 30, 2025 were
Complete financial results are available in the Company's Quarterly Report on Form 10Q for September 30, 2025, available at www.sec.gov.
Financial Highlights
Three Months Ended | Six Months Ended | |||||||||||||||
September 30, | September 30, | |||||||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||||||
Net revenues | $ | 887,498 | $ | 840,036 | $ | 1,861,173 | $ | 1,697,881 | ||||||||
Cost of sales | $ | 511,701 | $ | 421,254 | $ | 1,004,083 | $ | 758,196 | ||||||||
Gross Profit | $ | 375,797 | $ | 418,782 | $ | 857,090 | $ | 939,685 | ||||||||
Total Operating expenses | $ | 373,244 | $ | 464,640 | $ | 745,303 | $ | 821,262 | ||||||||
Income (loss) from operations | $ | 2,553 | $ | (45,858 | ) | $ | 111,787 | $ | 118,262 | |||||||
Total other income (expense) | $ | (117,225 | ) | $ | (6,329 | ) | $ | 102,675 | $ | 102,058 | ||||||
Net income (loss) | $ | (114,672 | ) | $ | (52,687 | ) | $ | 214,462 | $ | 219,481 | ||||||
Basic and diluted per common share | $ | (0.00 | ) | $ | (0.00 | ) | $ | 0.00 | $ | 0.00 | ||||||
Weighted average shares of common stock outstanding - basic and diluted | 67,588,492 | 67,588,492 | 67,588,492 | 67,588,492 | ||||||||||||
About ADMT
ADMT is a diversified, technology-based developer and manufacturer of innovative technologies and products. Its core competency is its ability to conceptualize a technology, bring it through development, into manufacturing and commercialization, all in-house. ADMT has three areas of activity: Proprietary Electronic Medical Devices; Design, Engineering, Regulatory and Manufacturing Services; and, Eco-Friendly, Safe, Water-Based Formulations. The Company's headquarters, laboratories, and FDA-Registered and ISO-13485 Certified medical device development and manufacturing operations are in Northvale, NJ. ADMT's multi-disciplinary team of engineers, researchers and technologists utilize advanced technology infrastructure, for the research, development and commercialization of diversified technologies. Additional information is available at admtronics.com
ADMT welcomes inquiries for its electronics and medical device contract engineering and manufacturing services at www.admteng.com.
To receive ADMT email updates, complete the form at https://admtronics.com/investor-relations/
Sonotron ® is a registered trademark of ADM Tronics Unlimited, Inc.
Except for historical information contained herein, the matters set forth in this news release are "forward-looking" statements (as defined in the Private Securities Litigation Reform Act of 1995), including statements regarding future revenue growth and performance. Although ADMT believes the expectations reflected in such forward-looking statements are based upon reasonable assumptions, there can be no assurance that its expectations will be realized. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from expectations. Factors that could contribute to such differences include those described from time to time in ADMT's filings with the SEC, news releases and other communications. The Company assumes no obligation to update the information contained in this news release.
Contact: Andre' DiMino 201-767-6040, andre@admtronics.com
SOURCE: ADM Tronics Unlimited Inc.
View the original press release on ACCESS Newswire
FAQ
What revenues did ADM Tronics (ADMT) report for the six months ending September 30, 2025?
What were ADM Tronics (ADMT) revenues and operating income for the quarter ended September 30, 2025?
What progress did ADM Tronics (ADMT) report on the Sonotron device on November 14, 2025?
Where can investors find ADM Tronics (ADMT) full financial results for Q2 FY2026?
How did ADM Tronics (ADMT) operating results compare year-over-year for the six months ended September 30, 2025?
Did ADM Tronics (ADMT) report net income for the quarter ended September 30, 2025?
